Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · None · Prevention
Enrollment
481actual
Sites
92
Countries
Belgium, Canada, Czechia +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-02-06 | actual | When the study began enrolling |
| Primary completion | 2025-09-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-23 | actual | The whole study's end, after follow-up |
| First posted | 2016-10-10 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stroke
Interventions
- Device: WATCHMAN LAAC Device Implant
- Drug: Single Antiplatelet Therapy or No Therapy (Control)
Primary outcomes
what the primary-completion date above is the date OFPrimary 7-Day Device/Procedural Safety Endpoint
measured 7 days
Primary Efficacy Endpoint - time to first event of ischemic stroke or systemic embolism.
measured 5 years
Publications
- PMID 31673900 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed